Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasoneindacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM) IRIDIUM trial investigators; Kerstjens, Huib A

Abstract-Passivation of Ge has been a critical issue for Ge MOS applications in future technology nodes. In this letter, we introduce ozone-oxidation to engineer Ge/insulator interface. Interface states (D it ) values across the bandgap and close to conduction bandedge were extracted using conductance technique at low temperatures. D it dependency on growth conditions was studied. Minimum D it of of 3x10 11 cm -2 V -1 was demonstrated. Physical quality of the interface was investigated through Ge 3d spectra measurements. We found that the interface and D it is strongly affected by the distribution of oxidation states and quality of the suboxide.

Dose-related efficacy and safety of fevipiprant (QAW039), an oral DP 2 (CRTh2) receptor antagonist, was assessed in patients with allergic asthma uncontrolled by low-dose inhaled corticosteroids (ICS).Adult patients were randomised to 12 weeks' treatment with once-daily (1,3,10, 30, 50, 75, 150, 300 Montelukast also demonstrated a significant improvement in this end-point. No impact on other efficacy end-points was observed. Adverse events were generally mild/moderate in severity, and were evenly distributed across doses and treatments.Fevipiprant appears to be efficacious and well-tolerated in this patient population, with an optimum total daily dose of 150 mg. Further investigations into the clinical role of fevipiprant in suitably designed phase III clinical trials are warranted.